Synaptoproteomics of Existing and new Animal Models of Depression
Autor: | Giorgio Racagni, Barbara Vollmayr, Daniela Tardito, Alessandra Mallei, Aleksander A. Mathé, V.S. Barbiero, Susanne H.M. Gruber, Laura Musazzi, R. Giambelli, Peter Gass, Aram El Khoury, Maurizio Popoli |
---|---|
Přispěvatelé: | C.W. Turck, Mallei, A, Giambelli, R, EL KHOURY, A, Gruber, S, Musazzi, L, Barbiero, V, Tardito, D, Vollmayr, B, Gass, P, Mathe, A, Racagni, G, Popoli, M |
Rok vydání: | 2008 |
Předmět: |
Drug
antidepressant business.industry media_common.quotation_subject Learned helplessness medicine.disease Synapse Mood disorders Animal models of depression depression medicine synaptoproteomic Antidepressant Escitalopram business Neuroscience Depression (differential diagnoses) media_common medicine.drug |
Zdroj: | Biomarkers for Psychiatric Disorders ISBN: 9780387792507 |
DOI: | 10.1007/978-0-387-79251-4_8 |
Popis: | Depression is a severe and life-threatening psychiatric illness whose pathogenesis is still essentially unknown. Proteomic analysis of synaptic terminals (synaptoproteomics) in animal models of depression is a powerful approach to gain insight into the molecular mechanisms underlying vulnerability to mood disorders and the long-term action of drug treatments. Here, we employed two different animal models of depression, the Learned Helplessness rats (a classical behavioral model of depression) and a new model of depression with gene - environment interaction (Flinders Sensitive Line rats subjected to early life stress). Both animal models were treated with the antidepressant escitalopram. Analysis of their synaptoproteomic profile revealed a number of protein spots differently regulated by basic vulnerability and/or early life stress. Using this approach, we obtained information regarding biomarkers that may represent predictors of pathology or response/resistance to drug treatment, as well as potential targets for novel pharmacological and therapeutic strategies. |
Databáze: | OpenAIRE |
Externí odkaz: |